Biocon, a leading biopharmaceutical company, plans to raise up to ₹45 billion ($540 million) through securities issuance, potentially via QIP or other methods. This move comes as the company experiences significant asset growth but faces increased liabilities and cash flow challenges. Recent financial data shows a 24.44% increase in total assets and a 145.45% rise in current assets, alongside a 238.46% surge in current liabilities. The company's cash flow from operating activities has turned negative, shifting from ₹0.20 billion to -₹0.10 billion year-over-year.